Spanish Intragastric Balloon Consensus Statement (SIBC): practical guidelines based on experience of over 20 000 cases
Background: intragastric balloons (IGBs) are a minimally inva-sive, increasingly popular option for obesity treatment. How-ever, there is only one worldwide guideline standardizing the technical aspects of the procedure (BIBC, SOARD 2018). Objectives: to construct a practical guideline for IGB usage...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p15527 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/15527 |
| Access Level: | acceso abierto |
| Palabra clave: | Consensus statement Intragastric balloon Endoscopy Bariatric endoscopy Obesity |
| Sumario: | Background: intragastric balloons (IGBs) are a minimally inva-sive, increasingly popular option for obesity treatment. How-ever, there is only one worldwide guideline standardizing the technical aspects of the procedure (BIBC, SOARD 2018). Objectives: to construct a practical guideline for IGB usage by reproducing and expanding the BIBC survey among the Spanish Bariatric Endoscopy Group (GETTEMO). Methods: a 140-question survey was submitted to all GETTE-MO members. Twenty-one Spanish experienced endoscopists in IGBs answered back. Eight topics on patient selection, indica-tions/contraindications, technique, multidisciplinary follow-up, results, safety, and financial/legal aspects were discussed. Con -sensus was defined when there was >= 70% agreement. Results: overall data included 20 680 IGBs including 12 dif-ferent models. Mean age was 42.0 years-old, 79.9 % were women, and the mean preoperative body mass index (BMI) was 34.05 kg/m2. Indication in BMI > 25 kg/m2, 10 absolute contraindications, and nutritional and medication measures at follow-up were settled. A mean %TBWL (total body weight loss) of 17.66 % +/- 2.5 % was observed. Early remov-al rate due to intolerance was 3.62 %. Adverse event rate was 0.70 % and 6.37 % for major and minor complications with consensual management. A single case of mortality occurred. IGBs were placed in private health, prior con-tract, and with full and single payment at the beginning. Seven lawsuits (0.034 %) were received, all ran through civil proceeding, and with favorable final resolution. Conclusions: this consensus based on more than 20 000 cases represents practical recommendations to perform IGB proce-dures. This experience shows that the device leads to satisfac-tory weight loss with a low rate of adverse events. Most results are reproducible compared to those obtained by the BIBC. |
|---|